BOULDER, Colo., Feb. 26 /PRNewswire-FirstCall/ -- Pharmion Corporation today announced that Institutional Shareholder Services (ISS) has recommended that Pharmion stockholders vote FOR the merger agreement with Celgene Corporation at the Special Stockholders Meeting scheduled for March 6, 2008. With this recommendation, all four of the leading proxy advisory firms, ISS, Glass Lewis & Co., PROXY Governance, Inc. and Egan-Jones Proxy Services, have now recommended that Pharmion stockholders support the merger with Celgene.
"We are pleased that ISS, as well as the other leading independent proxy advisory firms -- Glass Lewis & Co., PROXY Governance and Egan-Jones Proxy Services -- have all recognized the strategic and economic logic of our merger with Celgene," said Patrick Mahaffy, Pharmion's president and chief executive officer. "ISS' conclusions confirm our conviction that the merger offers the best value to Pharmion stockholders."
ISS is a leading independent U.S. proxy advisory firm and its voting analyses and recommendations are relied upon by hundreds of major institutional investment funds, mutual funds and fiduciaries throughout the country.
The Board of Directors of Pharmion unanimously recommends that stockholders vote "FOR" the approval and adoption of the agreement and plan of merger, and the approval of the merger as described in the proxy statement/prospectus and the supplement thereto.
Pharmion Corporation is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.
Additional Information about the Transaction and Where to Find It
This press release shall not constitute an offer of any securities for sale. The acquisition will be submitted to Pharmion's stockholders for their consideration. In connection with the acquisition, Celgene and Pharmion have filed with the SEC a registration statement, a proxy statement/prospectus (which was mailed to Pharmion stockholders on or about February 6, 2008), a supplement thereto (which was mailed to Pharmion stockholders on or about February 19, 2008), and other relevant documents concerning the merger. Investors and stockholders of Celgene and Pharmion are urged to read the registration statement, the proxy statement/prospectus, the supplement thereto and other relevant documents filed with the SEC, as well as any amendments or supplements to such documents because they contain important information about Celgene, Pharmion and the merger. The proxy statement/prospectus, the supplement thereto, the registration statement, other relevant materials and any other documents filed by Celgene and Pharmion with the SEC, may be obtained free of charge at the SEC's web site at http://www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by directing a written request to: Celgene Corporation, 86 Morris Ave., Summit, New Jersey 07901, Attention: Investor Relations, or Pharmion Corporation, 2525 28th Street, Suite 200, Boulder, Colorado 80301, Attention: Investor Relations. Investors and stockholders are urged to read the proxy statement/prospectus, the supplement thereto, the registration statement and the other relevant materials before making any voting or investment decision with respect to the merger.
Participants in Solicitations
Pharmion and its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from stockholders of Pharmion in connection with the merger. Information regarding Pharmion's directors and executive officers is available in Pharmion's proxy statement on Schedule 14 A for its 2007 annual meeting of stockholders, which was filed with the SEC on April 30, 2007. Additional information regarding the interests of such potential participants is included in the proxy statement/prospectus, as supplemented.
CONTACT: Breanna Burkart, Director, Investor Relations and Corporate
Communications, +1-720-564-9144, firstname.lastname@example.org, or Anna Sussman,
Director, Investor Relations and Corporate Communications, +1-720-564-9143,
email@example.com, both of Pharmion Corporation
Web site: http://www.pharmion.com/